Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin (Q34787395)

4 August 2017

1 reference

title

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin (English)

1 reference

4 August 2017

1 reference

1 reference

Mikko Niemi

3

0 references

author name string

Pertti J Neuvonen

series ordinal

1

1 reference

4 August 2017

Janne T Backman

series ordinal

2

1 reference

4 August 2017

publication date

1 January 2008

1 reference

Clinical Pharmacokinetics

4 August 2017

published in

1 reference

4 August 2017

volume

47

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

463-474

1 reference

Should cholesterol-lowering medications be available in Canada without a prescription?

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

21 January 2018

12 December 2020

Potentially fatal interaction between diltiazem and statins

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Statin-associated rhabdomyolysis triggered by grapefruit consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Efficacy of statin therapy: possible effect of phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847070-00003

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension

1 reference

12 December 2020

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

1 reference

12 December 2020

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

1 reference

12 December 2020

Statin safety: an overview and assessment of the data--2005.

1 reference

12 December 2020

Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin

1 reference

12 December 2020

Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease

1 reference

12 December 2020

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

1 reference

12 December 2020

Rhabdomyolysis and HMG-CoA reductase inhibitors

1 reference

12 December 2020

Interactions between grapefruit juice and cardiovascular drugs

1 reference

12 December 2020

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics

1 reference

12 December 2020

Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events

1 reference

12 December 2020

Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

1 reference

12 December 2020

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

1 reference

12 December 2020

Statins and over-the-counter availability

1 reference

12 December 2020

Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities

1 reference

12 December 2020

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

1 reference

12 December 2020

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

1 reference

12 December 2020

The interaction of diltiazem with simvastatin

1 reference

12 December 2020

Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

1 reference

12 December 2020

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

1 reference

12 December 2020

Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily

1 reference

12 December 2020

Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics

1 reference

12 December 2020

OTC statins: a bad decision for public health

1 reference

12 December 2020

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin

1 reference

12 December 2020

Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

12 December 2020

Clinical implications of pharmacogenomics of statin treatment

1 reference

12 December 2020

Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

12 December 2020

Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients

1 reference

12 December 2020

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

1 reference

12 December 2020

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

12 December 2020

Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine

1 reference

12 December 2020

Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature

1 reference

12 December 2020

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

12 December 2020

Transporters and drug therapy: implications for drug disposition and disease

1 reference

12 December 2020

Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease

1 reference

12 December 2020

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

1 reference

12 December 2020

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

1 reference

12 December 2020

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

1 reference

12 December 2020

Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin

1 reference

12 December 2020

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

1 reference

12 December 2020

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

12 December 2020

Clinical pharmacokinetics of fluvastatin

1 reference

12 December 2020

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

1 reference

12 December 2020

HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

1 reference

12 December 2020

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

1 reference

12 December 2020

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

1 reference

12 December 2020

Role of OATP transporters in the disposition of drugs

1 reference

12 December 2020

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

1 reference

12 December 2020

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

1 reference

12 December 2020

Potential drug interaction between simvastatin and danazol causing rhabdomyolysis

1 reference

12 December 2020

Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin

1 reference

12 December 2020

Rhabdomyolysis due to interaction of simvastatin with mibefradil

1 reference

12 December 2020

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

1 reference

12 December 2020

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

1 reference

12 December 2020

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

1 reference

12 December 2020

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

1 reference

12 December 2020

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

1 reference

12 December 2020

Drug therapy in the heart transplant recipient: Part III: common medical problems

1 reference

12 December 2020

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

1 reference

12 December 2020

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients

1 reference

12 December 2020

Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins

1 reference

12 December 2020

Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man

1 reference

12 December 2020

Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.

1 reference

12 December 2020

Statin safety: a systematic review

1 reference

12 December 2020

Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

1 reference

12 December 2020

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

1 reference

12 December 2020

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

1 reference

12 December 2020

Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers

1 reference

12 December 2020

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

1 reference

12 December 2020

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

1 reference

12 December 2020

Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.

1 reference

12 December 2020

Drug therapy in the heart transplant recipient: part IV: drug-drug interactions

1 reference

12 December 2020

FDA adverse event reports on statin-associated rhabdomyolysis

1 reference

12 December 2020

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

1 reference

12 December 2020

The interaction of diltiazem with lovastatin and pravastatin

1 reference

12 December 2020

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

1 reference

12 December 2020

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

1 reference

12 December 2020

Rhabdomyolysis due to probable interaction between simvastatin and ritonavir

1 reference

12 December 2020

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 reference

12 December 2020

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

12 December 2020

Primary prevention with over-the-counter statins: a cautionary tale

1 reference

12 December 2020

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression

1 reference

12 December 2020

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

1 reference

12 December 2020

Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus

1 reference

12 December 2020

Ethnic differences in statin disposition

1 reference

12 December 2020

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

1 reference

12 December 2020

Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients

1 reference

12 December 2020

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

1 reference

12 December 2020

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

1 reference

12 December 2020

Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Risk for myopathy with statin therapy in high-risk patients.

1 reference

12 December 2020

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

1 reference

12 December 2020

Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Rhabdomyolysis in association with simvastatin and amiodarone

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?

1 reference

12 December 2020

Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

1 reference

12 December 2020

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

12 December 2020

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

1 reference

12 December 2020

Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors

1 reference

12 December 2020

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

1 reference

12 December 2020

10.2165/00003088-200847070-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1047280545

0 references

1 reference